The Most Talked About Drug Class Since Statins Deserves An Honest Conversation
GLP-1 receptor agonists, the drug class that includes Wegovy and Ozempic, have gone from diabetes specialist prescribing to full cultural phenomenon in about four years flat. They're on magazine covers, in court documents, on shortage lists, and in the group chats of people who swear by them and people who are genuinely scared of them.
Neither camp is entirely right.
What the research actually shows is more interesting than the hype and more reassuring than the fear, with some genuine unknowns sitting in between. This is what we know, what we don't, what Australians can actually access, and what the clinical picture looks like for specific conditions like PCOS that are rarely discussed in the mainstream coverage.
What GLP-1 Drugs Actually Are
Semaglutide, the active molecule in both Wegovy and Ozempic, is a glucagon-like peptide-1 receptor agonist. That means it mimics a hormone your gut naturally produces after eating, one that signals fullness to the brain, slows gastric emptying, and modulates insulin release.
When that signalling system is working well, you eat, feel full, and stop. When it's dysregulated, by genetics, chronic stress, ultra-processed food environments, insulin resistance or a range of metabolic conditions, the off switch doesn't work the way it should.
GLP-1 drugs essentially turn the volume back up on satiety.
Wegovy (semaglutide 2.4mg weekly injection) is TGA approved in Australia for chronic weight management. Ozempic is the same molecule at lower doses, but it's TGA approved only for type 2 diabetes. The Wegovy pill, an oral version of semaglutide, was FDA approved in the US in December 2025 and is not yet available in Australia. Mounjaro (tirzepatide, made by Eli Lilly) works on both GLP-1 and GIP receptor pathways and is also TGA approved here for weight management since September 2024.
What The Science Actually Shows: The Compelling Part
Let's start with what the evidence genuinely supports, because this part tends to get lost in the noise.
Weight loss: Large phase 3 clinical trials show average weight reduction of 14 to 17 percent of body weight on semaglutide when combined with diet and increased physical activity. Tirzepatide (Mounjaro) achieves around 20 to 21 percent on average, currently the highest of any approved pharmacotherapy.
Cardiovascular outcomes: The SELECT trial, published in the New England Journal of Medicine, showed that semaglutide significantly reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with overweight or obesity and established cardiovascular disease. This is not a surrogate endpoint or a biomarker improvement. It's the hard clinical outcome that matters.
Metabolic improvement: Blood pressure, cholesterol, and blood glucose markers all improve meaningfully in clinical trials. For people whose metabolic health is under pressure, these are not trivial gains.
A 2024 Cochrane review confirmed GLP-1 medicines produce meaningful weight loss, while also noting, honestly, that most studies have been industry funded and that long-term safety evaluation is still in progress. Both things are true.
PCOS, Insulin Resistance And Why This Drug Class Matters For Women's Metabolic Health
This section rarely gets written because most GLP-1 coverage is framed around obesity as the primary indication. But for women with polycystic ovary syndrome, the research is some of the most clinically interesting in the field.
PCOS is fundamentally a metabolic and hormonal condition. Insulin resistance sits at the core of it for many women, driving elevated androgens, disrupted ovulation, irregular or absent periods, and often, fatty liver changes. For these women, the standard of care has historically been metformin and the oral contraceptive pill, both of which manage symptoms without addressing the root metabolic dysfunction very aggressively.
GLP-1 drugs appear to address that root cause more directly.
A 2023 clinical study found that low-dose semaglutide (0.5mg weekly) produced significant weight reduction in nearly 80 percent of women with PCOS who hadn't responded to lifestyle interventions. That weight improvement was directly associated with normalised menstrual cycles, improved HOMA-IR (the standard measure of insulin resistance), and lower androgen levels including testosterone.
A 2025 prospective randomised controlled trial compared semaglutide plus metformin against metformin alone in overweight and obese women with PCOS. The combination significantly outperformed metformin alone across weight, insulin resistance, inflammatory markers, menstrual cycle regulation, and, notably, natural pregnancy rates.
A 2025 meta-analysis published in Scientific Reports, reviewing randomised controlled trials, confirmed that GLP-1 receptor agonists improve weight, hormonal parameters and metabolic markers in women with PCOS.
The evidence is not yet at the level that would see a PCOS-specific TGA indication, but the mechanistic logic and the clinical trial data are pointing in the same direction. For women with PCOS, insulin resistance is often the engine, and GLP-1 drugs appear to address that engine.
One important note: most of these studies have involved women who also had obesity. Whether the benefit translates the same way to women with PCOS who are not obese is less established. An endocrinologist who can review the full clinical picture, including bloodwork and hormone panels, is the right person to make that call.
The Liver: What The Research Shows About GLP-1 And Fatty Liver Disease
Liver stress in the context of insulin resistance and metabolic dysfunction is increasingly understood as non-alcoholic fatty liver disease (NAFLD) or its more advanced form, non-alcoholic steatohepatitis (NASH), now also referred to as metabolic dysfunction-associated steatohepatitis (MASH).
The research here is striking.
A placebo-controlled phase 2 trial published in the New England Journal of Medicine found that semaglutide achieved NASH resolution with no worsening of fibrosis in 59 percent of patients, compared to 17 percent on placebo. Mean weight loss in the treatment group was 13 percent versus 1 percent in the placebo group.
A 2024 open-label controlled trial found statistically significant improvements in liver enzymes, liver fat scores (CAP measurements), and liver stiffness at both 6 and 12 months, particularly with injectable semaglutide.
In November 2025, the American Association for the Study of Liver Diseases updated its practice guidance to include semaglutide as a therapeutic option for MASH. This is not fringe clinical opinion. It is formal guidance from the peak liver disease body in the United States.
Liver enzyme improvement is one of the more consistent findings across GLP-1 trials, even in studies where liver health was not the primary endpoint, because reducing insulin resistance and driving weight loss reduces liver fat load.
The Honest Risks: What We Know And What We Don't Yet
Every medicine involves trade-offs. The ones with this class of drugs include some well-characterised effects and some genuinely open questions.
What's well established:
Gastrointestinal effects are the most common. Nausea, vomiting, diarrhoea, constipation and abdominal discomfort are reported in up to half of patients, particularly in the first months as dosing increases. These typically improve. They're also how the drug works: slowing gastric emptying is the mechanism behind both satiety and nausea.
Gallbladder disorders and acute pancreatitis are rare but documented serious adverse events. Rapid weight loss of any kind increases gallstone risk; this is not unique to GLP-1 drugs but is relevant to anyone with existing gallbladder history.
In mid-2025, the TGA updated safety information across the GLP-1 drug class to include stronger warnings about potential psychological effects, including the risk of suicidal thoughts or behaviours. This is a class-level regulatory update based on pharmacovigilance data, not a proven causal link. It reflects the regulator doing its job: monitoring real-world safety signals and informing prescribers and patients. Anyone starting GLP-1 therapy with a history of depression or other mood disorders should discuss this explicitly with their doctor.
Anaesthesia risk is also now documented. Delayed gastric emptying means residual stomach contents are more likely to be present than expected, which creates aspiration risk. People on GLP-1 drugs need to tell their anaesthetist. This should be on every pre-op checklist.
The long-term unknowns: this is where the honest conversation lives.
The short to medium-term safety profile has been characterised across more than 40 phase 3 trials. Long-term data is now only starting to emerge as people reach five-year follow-up.
Muscle and lean mass loss: Studies show that up to 25 to 40 percent of total weight lost on semaglutide can be lean mass, not fat. This is not trivial. Muscle is metabolic currency. A 2025 AAOS Annual Meeting review noted that five and ten-year musculoskeletal follow-up data are only just becoming available now, and that the long-term effects of GLP-1 therapy on bone and joint health remain poorly understood. Adequate protein intake and resistance training are not optional lifestyle additions on these medications. They are how you protect the outcome.
Bone density: A 2024 phase 2 RCT found that 52 weeks of once-weekly semaglutide reduced hip bone mineral density by 2.6 percent and lumbar spine density by 2.1 percent compared to placebo, with increased bone resorption and no compensatory increase in bone formation. For younger people on long-term therapy this warrants monitoring. For older adults and postmenopausal women the risk is more acute. A baseline DXA scan is now considered standard of care for anyone at musculoskeletal risk starting long-term GLP-1 therapy.
Thyroid: The FDA label carries a boxed warning about thyroid C-cell tumours based on rodent data at clinically relevant exposures. The human picture is more nuanced. A 2025 to 2026 large observational study published in Diabetes, Obesity and Metabolism found no association between liraglutide or semaglutide use and thyroid cancer risk in adults. However, a separate analysis found that GLP-1 RA use for one to three years was associated with a statistically elevated hazard ratio for thyroid cancer, including medullary thyroid carcinoma. Researchers acknowledge that the median follow-up in most studies, around 1.8 to 3 years, is likely insufficient to evaluate long-term risk.
The honest summary: there is no proven causal link between semaglutide and thyroid cancer in humans. There is also not yet enough long-term follow-up data to close the question definitively. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take these drugs. This is a hard contraindication, not a precaution.
Renal stress: Dehydration from GI side effects creates kidney load. eGFR monitoring is now standard in ongoing care.
What Monitoring Should Actually Look Like: The Tests
If a prescriber puts you on a GLP-1 medication without discussing baseline testing and an ongoing monitoring schedule, find a different prescriber.
Before starting (baseline):
-
HbA1c (glycated haemoglobin, reflects average blood glucose over three months)
-
Comprehensive metabolic panel: liver enzymes (ALT, AST), kidney function (eGFR, creatinine), electrolytes
-
TSH (thyroid stimulating hormone, to screen for existing thyroid disease before starting)
-
Fasting lipid panel
-
Fasting insulin and HOMA-IR if insulin resistance is part of the picture
-
FIB-4 score and liver function tests if any liver involvement is suspected
-
For anyone at musculoskeletal risk: baseline DXA scan
During treatment (every three to six months):
-
HbA1c and fasting glucose
-
Liver enzymes (ALT, AST): these often improve, but monitoring confirms the direction
-
eGFR and kidney function
-
Lipid panel
-
TSH annually, or every three to six months if on thyroid medication (weight loss affects thyroid hormone requirements)
-
Body composition assessment if available: tracking fat mass vs lean mass rather than just body weight gives a far more accurate picture of what the drug is actually doing
If symptoms develop: persistent abdominal pain warrants urgent lipase and amylase testing to rule out pancreatitis. This is a rare but serious adverse event and should not be dismissed.
Who These Drugs Are Actually Prescribed For
Wegovy is prescribed for adults with:
-
A BMI of 30 or above (classified as clinical obesity), or
-
A BMI of 27 or above plus a weight-related condition such as type 2 diabetes, high blood pressure, sleep apnoea, high cholesterol, or elevated cardiovascular risk
It is also approved to reduce the risk of heart attack and stroke in adults with established cardiovascular disease who have overweight or obesity.
For PCOS with insulin resistance, the relevant eligibility pathway is typically through the BMI threshold or through the insulin resistance classification as a weight-related metabolic condition. This is a conversation for an endocrinologist or GP with metabolic medicine experience.
These medications are not approved for people with normal BMI. People without clinical obesity can still lose weight on them. They also risk lean mass loss, disrupted natural appetite signalling, nutritional deficiency if intake drops too far, and rebound weight regain often weighted toward fat rather than muscle when they stop. The risk-to-benefit calculation looks very different for a person without metabolic disease.
Pregnancy, Fertility And The Two Month Rule
Semaglutide is not recommended during pregnancy and must be stopped at least two months before attempting to conceive. This is manufacturer guidance, FDA guidance, and standard clinical practice across the field.
The two month washout period is based on semaglutide's pharmacokinetics. The drug has a half life of approximately one week, which means it takes five to seven weeks for most of it to clear the body. The eight week recommendation adds a safety buffer to ensure no drug exposure during the earliest weeks of pregnancy, when organ development begins.
Animal studies raise legitimate concern. Pregnant rats, rabbits and cynomolgus monkeys given semaglutide at doses comparable to human use showed embryofetal mortality, structural abnormalities, early pregnancy losses and altered fetal growth. Many of these findings occurred alongside marked maternal weight loss and reduced food intake, which complicates interpretation, but the precautionary principle applies. The Australian TGA classifies semaglutide as Category D for pregnancy, meaning evidence of human fetal risk exists.
Human data remains limited. There is insufficient evidence to establish a clear association between semaglutide exposure and birth defects in humans, but equally, there is insufficient evidence to rule one out. A 2025 systematic review of 1,128 semaglutide exposed pregnancies found mixed results with no clear pattern, but the evidence base is too small and too heterogeneous to draw firm conclusions.
Weight loss during pregnancy is not recommended regardless of medication. Intentional caloric restriction or weight reduction in pregnancy is associated with infants who are small for gestational age and carries increased risks to both mother and fetus. Semaglutide's mechanism of action works directly against the nutritional requirements of pregnancy.
The fertility paradox is real but requires careful handling. For women with PCOS or insulin resistance, semaglutide can restore ovulation and regular menstrual cycles, which has led to a wave of unplanned pregnancies in women who believed they were not fertile. This is medically documented, clinically significant, and frequently underdiscussed. If you are taking semaglutide and do not wish to conceive, reliable contraception is not optional. If you do wish to conceive, the planning window needs to account for the two month washout before actively trying.
If pregnancy is discovered while on semaglutide, stop the medication immediately and contact your prescriber. Most early exposures have resulted in healthy pregnancies, but ongoing treatment is contraindicated.
What Happens When You Stop
Most people who stop GLP-1 therapy regain a substantial proportion of the lost weight within one to two years. The Guardian reported in 2026 on a study confirming this is the typical trajectory.
This is not a failure of the drug. It is how obesity biology works. The underlying drivers, whether genetic, metabolic, environmental, or hormonal, do not disappear because you spent a year on medication. When the pharmacological intervention stops, the biology reasserts.
For people who have also lost lean muscle mass during treatment, the picture is worse: weight may return with a higher fat percentage than before, which worsens metabolic outcomes.
This is the reason responsible clinicians frame GLP-1 therapy as a chronic treatment for a chronic condition rather than a 12-week reset. Whether that's the right framework for any individual depends on their health history, their metabolic risk, and an honest conversation with their doctor about what long-term therapy means for them.
What Australians Can Actually Access Right Now
Wegovy injection (semaglutide 2.4mg weekly) TGA approved for chronic weight management. Available at Australian pharmacies with a private prescription. Not PBS listed; Novo Nordisk has applied for PBS inclusion but approval is not expected before late 2026. Current private prescription cost: approximately $395 a month, though this varies by dose and pharmacy.
Mounjaro (tirzepatide weekly injection, by Eli Lilly) TGA approved for chronic weight management since September 2024, and more recently for moderate to severe obstructive sleep apnoea in adults with obesity. Works on both GLP-1 and GIP receptor pathways. Clinical trials show average weight loss of around 20 to 21 percent of body weight. Not PBS listed. Current cost: approximately $280 to $750 a month depending on dose.
Contrave (naltrexone and bupropion oral tablet) TGA approved for weight loss since 2019. Works on brain appetite and reward pathways rather than GLP-1. Average additional weight loss around 4 to 5 kg. Around $240 a month on private prescription.
Duromine (phentermine) An older stimulant appetite suppressant. TGA approved for short-term use only. Approximately $100 to $140 a month.
Xenical (orlistat) Works by blocking fat absorption in the gut. Available over the counter at lower doses or by prescription at higher doses. Around $120 a month.
What about the Wegovy pill? The oral semaglutide tablet was FDA approved in December 2025 and is available in US pharmacies at a list price of around USD $1,349 a month, though discount programs reduce this significantly for US patients. As of the time of writing, Novo Nordisk has not lodged a TGA application for the pill in Australia. There is no approval, no pharmacy stocking it, and no legal pathway to import it. Anyone selling it to Australians right now is either supplying compounded semaglutide (unapproved by the TGA and explicitly warned against) or operating outside the regulatory framework.
What about Ozempic? Ozempic contains semaglutide at doses approved for type 2 diabetes only. Off-label prescribing for weight loss is possible but sits in a regulatory grey zone, and during the 2023 to 2025 global shortage prescribers were specifically asked to stop this practice so that people with diabetes could access their medication. If weight management without diabetes is the goal, Wegovy is the correct TGA-approved product to discuss with your doctor.
What about compounded semaglutide? The TGA has issued explicit public warnings about compounded semaglutide being sold through some telehealth clinics and compounding pharmacies. These are unapproved goods that have not been assessed for safety, quality or efficacy. They are not equivalent to Wegovy or Ozempic, regardless of how they're marketed. In 2025 the TGA accepted a court enforceable undertaking from a compounding pharmacy over advertising these products. If it sounds like a shortcut, that's because it is.
The Commercial Context Is Worth Understanding
Wegovy and Ozempic are made by Novo Nordisk, a Danish pharmaceutical company that has become one of the most valuable companies in Europe on the back of GLP-1 revenues. This matters not because it makes the drugs dangerous, but because financial scale shapes research priorities, marketing, prescribing culture, and how risk information gets communicated.
In 2017 Novo Nordisk paid roughly USD $58.7 million to resolve US Department of Justice allegations that its sales force had downplayed risk information to doctors about Victoza, an earlier diabetes drug in the same class. The company did not admit wrongdoing, but the case established that big pharma and full transparency are not automatically synonymous.
This doesn't change the clinical trial data. It does mean that reading product claims with adult scepticism is not paranoia. It's appropriate.
The Bottom Line
GLP-1 drugs are not a fad, a moral failing, or a magic fix. They are a clinically serious class of medicines with strong evidence for meaningful outcomes in the right people, real but manageable known side effects, and some genuinely unresolved long-term questions that responsible medicine should be tracking honestly.
For people with clinical obesity, insulin resistance, PCOS, established cardiovascular risk, or metabolic liver disease, the benefit-to-risk calculation for supervised GLP-1 therapy looks compelling. The research backs that up.
The unknowns, particularly around long-term muscle and bone effects, are real. They are manageable with proper monitoring, adequate protein intake, resistance training, and a prescriber who does the full workup rather than just writing a script.
For people without metabolic disease who want to lose weight because culture made them feel they should, the risk-to-benefit calculation is very different.
If you're wondering whether this is right for you, the only person who can answer that is a doctor who knows your bloodwork, your history and your actual clinical picture. Not a telehealth platform with a 10-minute consult window. Not a TikTok comment section. A real clinical conversation.
This article is for general information only and does not constitute medical advice. Speak with your doctor before starting, stopping or changing any prescription medication.
Sources:
-
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM
-
Semaglutide: Double-edged Sword with Risks and Benefits, PMC
-
Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists, PMC
-
The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in PCOS, PMC
-
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, PMC
-
Effects of combined metformin and semaglutide therapy in PCOS women, PMC
-
Efficacy and safety of GLP-1 receptor agonists on weight management in PCOS, Scientific Reports
-
A Placebo-Controlled Trial of Subcutaneous Semaglutide in NASH, NEJM
-
Semaglutide therapy for MASH: November 2025 updates to AASLD Practice Guidance, PubMed
-
The Effects of GLP-1 Agonists on Musculoskeletal Health, PMC
-
Studies explore GLP-1 receptor agonist use and long-term musculoskeletal health, AAOS 2026
-
Assessment of thyroid cancer risk associated with GLP-1 RA use, Diabetes Obesity and Metabolism 2026
-
Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, PMC
